- Home
- CPZ vs AVIR Comparison
CPZ vs AVIR Comparison
Compare CPZ & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPZ
- AVIR
- Stock Information
- Founded
- CPZ 2019
- AVIR 2012
- Country
- CPZ United States
- AVIR United States
- Employees
- CPZ N/A
- AVIR N/A
- Industry
- CPZ Trusts Except Educational Religious and Charitable
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- CPZ Finance
- AVIR Health Care
- Exchange
- CPZ Nasdaq
- AVIR Nasdaq
- Market Cap
- CPZ 306.8M
- AVIR 290.4M
- IPO Year
- CPZ N/A
- AVIR 2020
- Fundamental
- Price
- CPZ $15.63
- AVIR $3.59
- Analyst Decision
- CPZ
- AVIR Hold
- Analyst Count
- CPZ 0
- AVIR 1
- Target Price
- CPZ N/A
- AVIR $6.88
- AVG Volume (30 Days)
- CPZ 63.0K
- AVIR 153.0K
- Earning Date
- CPZ 01-01-0001
- AVIR 11-06-2024
- Dividend Yield
- CPZ 11.07%
- AVIR N/A
- EPS Growth
- CPZ N/A
- AVIR N/A
- EPS
- CPZ N/A
- AVIR N/A
- Revenue
- CPZ N/A
- AVIR N/A
- Revenue This Year
- CPZ N/A
- AVIR N/A
- Revenue Next Year
- CPZ N/A
- AVIR N/A
- P/E Ratio
- CPZ N/A
- AVIR N/A
- Revenue Growth
- CPZ N/A
- AVIR N/A
- 52 Week Low
- CPZ $13.17
- AVIR $2.77
- 52 Week High
- CPZ $16.11
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- CPZ 51.16
- AVIR 50.72
- Support Level
- CPZ $15.44
- AVIR $3.31
- Resistance Level
- CPZ $15.70
- AVIR $3.49
- Average True Range (ATR)
- CPZ 0.18
- AVIR 0.12
- MACD
- CPZ -0.02
- AVIR 0.04
- Stochastic Oscillator
- CPZ 36.19
- AVIR 52.21
About CPZ Calamos Long/Short Equity & Dynamic Income Trust
Calamos L/S Equity & Dynamic Inc Trust is a trust company which seeks to provide current income and risk-managed capital appreciation. The company invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary and others.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).